FY23: Increasing Federal Funding for Breast Cancer Research and NCIs

We ask Congress to…

support increased funding for cancer research & prevention programs with at least $49 billion for the National Institutes of Health (NIH), including $7.7 billion for cancer research at the National Cancer Institute (NCI). AND, support $462.6 million for the Centers for Disease Control and Prevention’s (CDC) cancer programs, including $225 million for the National Breast and Cervical Cancer Early Detection Program.

Why does it matter?

NIH, NCI, and CDC funding has been linked to better health outcomes. Moreover, they provide research grants for universities and organizations who work on developing new therapies and medications. These organizations lead the world in finding novel treatments to cancer and other deadly diseases.

What are we doing?

The American Cancer Society advocated for increased research funding at the National Summit and Lobby Day where volunteers persuade lawmakers to approve an increased budget for the CDC, NIH, and NCI. 

How can you help?

Volunteers and local community members can help by posting on social media, calling district representatives, and email district representatives. Moreover, they can create easy-to-read infographics that can help spread the word of this crucial increase in budget. 

In Summary

Throughout the year, advocates have been pushing key legislative priorities that will save lives from cancer. Our advocacy efforts have focused on policies that prioritize prevention, detection, treatment and survivorship. With the 117th Congress quickly coming to a close, now is the time to capitalize. ACS CAN advocates have the chance to end the year on a high note with wins for people with cancer, survivors and their families.

Everyone has an end of year must-do list. For Congress, the must-do list is to save lives from cancer by prioritizing prevention, detection, treatment and survivorship in the FY 23 budget.

To end cancer as we know it, Congress must take swift action to: 

  1. Fund prevention that works and research for the cancers where we don't have answers 

  2. Support increased access to innovative cancer early detection in Medicare 

  3. Improve quality of life for cancer patients at all ages and stages.

Previous
Previous

HR5030/S2706: DIVERSE Trials Act

Next
Next

SB912 (Limón): Access to Biomarker Testing